BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16608883)

  • 1. GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations.
    Deacon CF; Plamboeck A; Rosenkilde MM; de Heer J; Holst JJ
    Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E468-75. PubMed ID: 16608883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GIP(3-30)NH
    Sparre-Ulrich AH; Gabe MN; Gasbjerg LS; Christiansen CB; Svendsen B; Hartmann B; Holst JJ; Rosenkilde MM
    Biochem Pharmacol; 2017 May; 131():78-88. PubMed ID: 28237651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs.
    Deacon CF; Danielsen P; Klarskov L; Olesen M; Holst JJ
    Diabetes; 2001 Jul; 50(7):1588-97. PubMed ID: 11423480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP).
    Hinke SA; Manhart S; Pamir N; Demuth H; W Gelling R; Pederson RA; McIntosh CH
    Biochim Biophys Acta; 2001 May; 1547(1):143-55. PubMed ID: 11343800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors.
    Sparre-Ulrich AH; Hansen LS; Svendsen B; Christensen M; Knop FK; Hartmann B; Holst JJ; Rosenkilde MM
    Br J Pharmacol; 2016 Jan; 173(1):27-38. PubMed ID: 26359804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
    Ahrén B; Hughes TE
    Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GIP(3-30)NH
    Gasbjerg LS; Christensen MB; Hartmann B; Lanng AR; Sparre-Ulrich AH; Gabe MBN; Dela F; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    Diabetologia; 2018 Feb; 61(2):413-423. PubMed ID: 28948296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats.
    Hinke SA; Gelling RW; Pederson RA; Manhart S; Nian C; Demuth HU; McIntosh CH
    Diabetes; 2002 Mar; 51(3):652-61. PubMed ID: 11872663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor.
    Hansen LS; Sparre-Ulrich AH; Christensen M; Knop FK; Hartmann B; Holst JJ; Rosenkilde MM
    Br J Pharmacol; 2016 Mar; 173(5):826-38. PubMed ID: 26572091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat.
    Tseng CC; Kieffer TJ; Jarboe LA; Usdin TB; Wolfe MM
    J Clin Invest; 1996 Dec; 98(11):2440-5. PubMed ID: 8958204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
    Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
    Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide.
    Gault VA; O'Harte FP; Harriott P; Flatt PR
    Biochem Biophys Res Commun; 2002 Feb; 290(5):1420-6. PubMed ID: 11820780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
    Green BD; Gault VA; Flatt PR; Harriott P; Greer B; O'Harte FP
    Arch Biochem Biophys; 2004 Aug; 428(2):136-43. PubMed ID: 15246869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The enteroinsular axis in dipeptidyl peptidase IV-negative rats.
    Pederson RA; Kieffer TJ; Pauly R; Kofod H; Kwong J; McIntosh CH
    Metabolism; 1996 Nov; 45(11):1335-41. PubMed ID: 8931636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice.
    O'Harte FP; Hunter K; Gault VA; Irwin N; Green BD; Greer B; Harriott P; Bailey CJ; Flatt PR
    Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1674-82. PubMed ID: 17299087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.
    Gault VA; Flatt PR; Bailey CJ; Harriott P; Greer B; Mooney MH; O'harte FP
    Biochem J; 2002 Nov; 367(Pt 3):913-20. PubMed ID: 12150711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human GIP(3-30)NH
    Gabe MBN; Sparre-Ulrich AH; Pedersen MF; Gasbjerg LS; Inoue A; Bräuner-Osborne H; Hartmann B; Rosenkilde MM
    Biochem Pharmacol; 2018 Apr; 150():97-107. PubMed ID: 29378179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.
    Deacon CF; Plamboeck A; Møller S; Holst JJ
    Am J Physiol Endocrinol Metab; 2002 Apr; 282(4):E873-9. PubMed ID: 11882507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP.
    O'Harte FP; Gault VA; Parker JC; Harriott P; Mooney MH; Bailey CJ; Flatt PR
    Diabetologia; 2002 Sep; 45(9):1281-91. PubMed ID: 12242461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.